Korro Bio, Inc. (KRRO) Stock Price & Analysis
Korro Bio, Inc. (KRRO) rose 3.31% to USD 10.94 as of June 10, 2026 at 03:44 UTC, according to Nexqual real-time market data.
KRRO last closed at USD 10.59; the session ranged USD 10.49–11.25 on volume of 116,101 shares. Market capitalization is $157.78M, with a 52-week range of USD 5.2–55.89 (NCM). Source: Nexqual, June 10, 2026 at 03:44 UTC.
Key Statistics (as of June 10, 2026 at 03:44 UTC)
| Price | USD 10.94 |
|---|---|
| Change | ▲ 3.31% (up) |
| Previous Close | USD 10.59 |
| Open | USD 10.78 |
| Day Range | USD 10.49 – 11.25 |
| 52-Week Range | USD 5.2 – 55.89 |
| Volume | 116,101 shares |
| Market Cap | $157.78M |
| Exchange | NCM |
Technical Analysis (KRRO)
Nexqual's technical model rates KRRO "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:44 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.01 (neutral) |
| vs SMA50 | Below (USD 12.4) |
| MACD | -0.31 (negative) |
Analyst Ratings (KRRO)
Wall Street analysts rate KRRO "Strong Buy" based on 10 analysts, with a mean price target of USD 20 (range USD 8–30), per Nexqual as of June 10, 2026 at 03:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 20 |
| High Target | USD 30 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (KRRO)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -1.28 |
| Revenue Estimate | $166,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.69 vs est -1.98 ▲ beat |
| 2025-12-31 | USD -1.65 vs est -2.14 ▲ beat |
| 2025-09-30 | USD -1.92 vs est -2.68 ▲ beat |
| 2025-06-30 | USD -2.74 vs est -2.59 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financials & Fundamentals (KRRO)
| Total Revenue | $3.84M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -2154.03% |
| Profit Margin | +0.00% |
| ROE | -87.78% |
| Debt / Equity | 35.85 |
| Current Ratio | 8.13 |
| Total Cash | $113.97M |
| Total Debt | $42.88M |
| Free Cash Flow | $-39.04M |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Financial Health Score (KRRO)
Nexqual rates Korro Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:44 UTC.
| Growth | Strong — Revenue +181% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $114M cash vs $43M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$39M, burning cash |
| Efficiency | Critical — ROE -88%, ROA -26.8% |
Ownership (KRRO)
| Insider Ownership | +0.96% |
|---|---|
| Institutional Ownership | +96.89% |
| Shares Outstanding | 14.42M |
| Float | 9.29M |
| Short % of Float | +9.85% |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
Leadership (KRRO)
Korro Bio, Inc. is led by Ram Aiyar (age 47), CEO, President, Interim CFO, Principal Financial Officer & Director, per Nexqual as of June 10, 2026 at 03:44 UTC.
| CEO, President, Interim CFO, Principal Financial Officer & Director | Ram Aiyar (age 47) |
|---|---|
| Chief Scientific Officer | Loic Vincent |
| Chief Operating Officer | Todd Chappell (age 52) |
Major Backers & Investors (KRRO)
Notable institutional backers of Korro Bio, Inc. include Lynx1 Capital Management Lp, NEA Management Company, LLC, Atlas Venture Life Science Advisors, LLC , according to Nexqual as of June 10, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lynx1 Capital Management Lp | 10.67% |
| NEA Management Company, LLC | 9% |
| Atlas Venture Life Science Advisors, LLC | 7.88% |
| Balyasny Asset Management LP | 7.21% |
| Venrock Adviser, LLC | 7% |
| Affinity Asset Advisors, Llc | 4.9% |
| Nantahala Capital Management, LLC | 4.58% |
| Adar1 Capital Management, LLC | 3.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.76% |
Source: Nexqual, June 10, 2026 at 03:44 UTC.
From Korro Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.
- The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
- It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
- The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TIL | Instil Bio, Inc. | USD 8.02 | ▼ 0.62% |
| SGMT | Sagimet Biosciences Inc. - Seri | USD 6.52 | ▼ 3.55% |
| VEEA | Veea Inc. | USD 0.41 | ▼ 6.59% |
| SRZN | Surrozen, Inc. | USD 21.5 | ▼ 0.09% |
| TVGN | Tevogen Bio Holdings Inc. | USD 10.75 | ▲ 2.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:44 UTC. This page is informational and not investment advice.